Angiogenèse et cancer de vessie: marqueur tumoral à la mode ou nouvelle cible thérapeutique [Angiogenesis and bladder cancer: trendy prognostic factor or new therapeutic target?].

Détails

ID Serval
serval:BIB_7FE17BC09C02
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Angiogenèse et cancer de vessie: marqueur tumoral à la mode ou nouvelle cible thérapeutique [Angiogenesis and bladder cancer: trendy prognostic factor or new therapeutic target?].
Périodique
Annales d'urologie
Auteur⸱e⸱s
Jayet C., Deperthes D., Leisinger H.J.
ISSN
0003-4401 (Print)
ISSN-L
0003-4401
Statut éditorial
Publié
Date de publication
07/2002
Peer-reviewed
Oui
Volume
36
Numéro
4
Pages
258-263
Langue
français
Notes
Publication types: Comparative Study ; English Abstract ; Journal Article ; Review
Publication Status: ppublish
Résumé
Tumor-associated angiogenesis is emerging as an important prognostic factor and represents a hopeful potential therapeutic target for the cancer treatment. Bladder tumors, as all solid tumors, require an active angiogenesis to support their growth and progression. The angiogenic phenotype observed within a tumor is determined in large part by the balance between stimulatory and inhibitory inputs to the endothelial cells. Clinically, the importance of the angiogenic response observed within a tumor should be considered as an independent prognostic factor for superficial as well as invasive bladder tumors. The analysis of the angiogenic response could in the future influence the therapeutic strategy. Angiogenesis also represents a promising new therapeutic target, and is at the moment intensively tested in experimental and clinical trials. In this article, we will first review the mechanism of angiogenesis, and then its implication in bladder cancer, and as a potential therapeutic target.
Mots-clé
Angiogenesis Inducing Agents/antagonists & inhibitors, Angiogenesis Inducing Agents/physiology, Angiogenesis Inhibitors/therapeutic use, Animals, Antineoplastic Agents/therapeutic use, Carcinoma, Transitional Cell/diagnosis, Carcinoma, Transitional Cell/drug therapy, Carcinoma, Transitional Cell/</QualifierName> <QualifierName MajorTopicYN="N">, Clinical Trials as Topic, Collagen/therapeutic use, Endostatins, Fibroblast Growth Factor 2/antagonists & inhibitors, Humans, Lymphatic Metastasis, Mice, Mice, Nude, Neoplasm Transplantation, Neovascularization, Pathologic/drug therapy, Peptide Fragments/therapeutic use, Phenotype, Prognosis, Rabbits, Research, Retrospective Studies, Risk Factors, Thrombospondin 1/physiology, Urinary Bladder Neoplasms/diagnosis, Urinary Bladder Neoplasms/drug therapy, Urinary Bladder Neoplasms/</QualifierName> <QualifierName MajorTopicYN="N">
Pubmed
Web of science
Création de la notice
21/01/2008 16:10
Dernière modification de la notice
20/08/2019 14:40
Données d'usage